The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?

Nossov, Vladimir; Amneus, M.; Su, Feng; Lang, Jennifer M.; Janco, Jo Marie Tran; Reddy, Srinivasa T.; Farias‐Eisner, Robin

doi:10.1016/j.ajog.2008.04.009

Cited by 253 publications

(212 citation statements)

References 78 publications

Supporting

Mentioning

198

Contrasting

Unclassified

Order By: Relevance

“…Currently, cancer antigen 125 (CA-125) is the most common biomarker for ovarian screening. However as an individual marker on a single occasion, CA-125 is not sufficiently sensitive and specify to detect most cases of ovarian cancer (Gadducci et al, 2004;Nossov et al, 2008). With appropriate statistical models, combinations of several markers such as leptin, prolactin, osteopon-tin, insulin-like growth factor II (IGF-II), macrophage inhibitory factor (MIF) and CA-125 have become more effective and accurate means for the detection of ovarian tumorgenesis (Visintin et al, 2008;Li et al, 2009;Sorensen et al, 2011), while no reliable method can be used to distinguish tumor stages.…”

Section: Discussionmentioning

confidence: 99%

ATAD2 is Highly Expressed in Ovarian Carcinomas and Indicates Poor Prognosis

Wan¹,

Zhang²,

Wang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The purpose of this study was to explore the expression of ATAD2 in ovarian tumor tissue as well as its relationship with degree of malignancy. Tumor tissue from 110 cases of ovarian cancer was collected in accordance with the Declaration of Helsinki for evaluation of ATAD2 expression iimmunohistochemistry, quantitative PCR (qPCR) and Western blotting. The correlation between the ATAD2 expression and and the prognosis of ovarian cancer was evaluated by Cox regression model. In addition, HO-8910 and OVCAR-3 cells were transfected with two siRNAs targeting ATAD2. Cell viability was evaluated with MTT assay, and cell migration by transwell migration assay. ATAD2 was shown to be highly expressed in 65.5% (72/110) of ovarian cancer cases, both at transcriptional and protein levels. Moreover, highly expression was positively correlated with degree of malignancy. Knock-down of ATAD2 in HO-8910 and OVCAR-3 cells was found to reduce cell migration. In addition, follow-up visits of the patients demonstrated that the 5-year survival rate was lower in patients with high expression of ATAD2. Our study suggested that ovarian tumor tissue may have highly expressed ATAD2, which is associated with tumor stage, omentum-metastasis, ascites and CA-125. Increased ATAD2 may play important roles in tumor proliferation and migration. ATAD2 could serve in particular as a prognostic marker and a therapeutic target for ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

ATAD2 is Highly Expressed in Ovarian Carcinomas and Indicates Poor Prognosis

Wan¹,

Zhang²,

Wang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…2e), even though relatively low levels of serum CA125 have been reported in these populations. [22][23][24][25] As the mesothelin-binding ability of CA125 is a key factor for the CA125 meso assay, the difference in CA125 meso /CA125 levels between patients with endometriosis and EOC implies that this assay may have an advantage over the conventional antibody-based CA125 assay for a differential diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Difference in mesothelin‐binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer

Sasaki

Akita

Ito

et al. 2014

Intl Journal of Cancer

View full text Add to dashboard Cite

The epithelial ovarian carcinoma (EOC) is an aggressive malignant tumor, and is currently the leading cause of gynecologic cancer death. CA125 is the most commonly used serum marker for EOC, but shows a high-false-positive rate for several benign diseases such as endometriosis. The purpose of our study is therefore to identify a useful biochemical tool for detecting qualitative differences between CA125 from patients with endometriosis and EOC, and to facilitate differential diagnosis of these diseases. In our study, using two different CA125-binding molecules, i.e., recombinant mesothelin and an anti-CA125 monoclonal antibody, a novel sandwich ELISA for determining the serum levels of CA125 with mesothelin-binding ability (CA125 meso ) was developed, and tested for patients with endometriosis (n 5 59) and EOC (n 5 36). We found that both the serum CA125 meso level and the ratio of the serum CA125 meso to CA125 levels (CA125 meso /CA125) were significantly higher in patients with EOC than in patients with endometriosis (p < 0.00005 and p < 0.000001, respectively). Furthermore, receiver operating characteristic analysis showed that the CA125 meso assay was superior to the conventional antibody-based CA125 assay in discriminating endometriosis from EOC. Thus, mesothelin-binding ability may be a useful indicator for qualitatively evaluating CA125 in patients with endometriosis and EOC.

show abstract

“…Second, current screening methods for early detection of ovarian cancer, including routine physical examination, CA125 serum assessment, and transvaginal ultrasound, have high false-positive rates and low positive predictive values ( Table 1) 20 . In fact, for a positive predictive value (PPV) of 10%, an ovarian cancer screening test would require a sensitivity of at least 75% and a specificity of greater than 99% 22 . Further, current methods of screening have not resulted in a significant impact on disease morbidity or mortality 21 .…”

Section: Challenges In Ovarian Cancer Preventionmentioning

confidence: 99%